The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom fro…

Delayed Graft FunctionDGFKidney Transplant

~Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT06830798

Phase 1

A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation

The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusio…

Ischemia Reperfusion InjuryDelayed Graft Function

~Estimated

~$10 – $6,250

Rhode Island HospitalNCT04005469